Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting disciplined cost management and strategic investments [8][28] - The adjusted gross margin for the fourth quarter was 70%, down approximately 190 basis points year-over-year due to the revenue headwind from GeneSight [9][26] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by a 12% increase in test volume [16][17] - Women's health revenue was $88.5 million, reflecting a 2% increase year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] Market Data and Key Metrics Changes - GeneSight volume grew 9% year-over-year, with a record number of ordering clinicians reaching over 38,000 [22] - The company faced challenges in prenatal testing, with a decline in volume due to order management disruptions, but expects recovery in 2026 [21][22] - The mental health segment showed resilience, with GeneSight revenues impacted by UnitedHealthcare's coverage policy change but still achieving positive coverage policies across 12 payers [23] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - A significant investment of over $35 million is planned to enhance organizational efficiency and commercial capabilities, particularly in the cancer care continuum [15][60] - The company aims to strengthen its position across cancer care testing while leveraging operational strengths for sample processing and reporting [33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, driven by new product launches and recovery in the prenatal business [39] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and expects to regain share in the prenatal market [20][21] - Management emphasized the importance of execution excellence and rigorous testing before launching new products to avoid past issues [82] Other Important Information - The company plans to simplify its reporting structure to align with its refreshed strategy, focusing on cancer care continuum, prenatal health, and mental health as distinct categories [31] - The company maintains a solid balance sheet with access to $225 million in capital and intends to file a universal shelf registration [28] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted several growth drivers for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [38] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but expects recovery in Q2 and beyond, supported by a focused sales team and new product launches [44][76] Question: Prolaris momentum - Management noted that various initiatives, including engagement with KOLs and sales team expansion, contributed to Prolaris' growth, while also acknowledging potential favorable comparisons in Q4 [71][73]